scholarly journals Localized Biphasic Malignant Peritoneal Mesothelioma with Rhabdoid Features Involving the Liver: Case Report and Review of the Literature

2019 ◽  
Vol 2019 ◽  
pp. 1-7
Author(s):  
Dalal Hassan ◽  
Saverio Ligato
Keyword(s):  
Abdominal Wall ◽  
Surgical Resection ◽  
Asbestos Exposure ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma ◽  
Microscopic Appearance ◽  
Lateral Abdominal Wall ◽  
Rare Tumors ◽  
History Of ◽  
Rhabdoid Features

Introduction. Localized malignant mesotheliomas, defined as sharply circumscribed tumors of the serosal membrane with the microscopic appearance of diffuse malignant mesothelioma, are rare tumors; their behavior and prognosis are uncertain. Intrahepatic mesotheliomas are postulated to arise from mesothelial cells of Glisson’s capsule. Case Presentation. A 69-year-old female with no history of asbestos exposure presented with a one-month history of increasing abdominal pain associated with constitutional symptoms. Computerized Tomography (CT) scan of the abdomen and pelvis revealed a sizable soft tissue mass within the right paracolic gutter, abutting the inferior hepatic margin, the lateral abdominal wall, and descending colon. Ultrasound-guided biopsy of the mass suggested a poorly differentiated hepatocellular carcinoma. There was no disease elsewhere on PET scan. Surgical resection of the mass was performed. Pathological assessment suggested the tumor to be arising from the liver with invasion of the liver, abdominal wall musculature, and the adventitial surface of the ascending colon. A final diagnosis of localized biphasic malignant peritoneal mesothelioma with rhabdoid features was rendered based on morphology and the result of immunohistochemical studies. The abdominal wall margin was positive. The patient progressed over the course of 6 months despite receiving adjuvant chemotherapy and immunotherapy with metastases and a decline in performance status and was transitioned to hospice. Conclusion. Localized malignant peritoneal mesotheliomas are rare tumors that may present clinically as a liver mass and simulate primary hepatic or secondary tumors. Definitive diagnosis is obtained by surgical resection in most cases. The clinical outcome is variable with most cases having a poor outcome.

scholarly journals Multidisciplinary Approach to Diagnosing and Managing a Case of Peritoneal Mesothelioma

2020 ◽  
pp. 68-83
Author(s):  
Jonathan Maw ◽  
Geoffrey Kelly ◽  
Miriam Enriquez ◽  
Ronak Gor ◽  
Pauline Germain
Keyword(s):  
Multidisciplinary Approach ◽  
Asbestos Exposure ◽  
Peritoneal Mesothelioma ◽  
Review Of Literature ◽  
Malignant Peritoneal Mesothelioma ◽  
History Of

Peritoneal mesothelioma is a rare cause of a peritoneal mass in adults and can occur in malignant or benign forms. Compared to the pleural variant of mesothelioma, the peritoneal form is understudied due to the small number of reported cases. We present a case of an 84-year-old male with a history of asbestos exposure who initially presented for an aggravated hernia, was found to have an incidental mass on imaging, and ultimately was diagnosed with malignant peritoneal mesothelioma (MPM)1 likely related to prior asbestos exposure. This case study will provide a review of literature and discuss the role of imaging for MPM.

scholarly journals Malignant Peritoneum Mesothelioma with Hepatic Involvement: A Single Institution Experience in 5 Patients and Review of the Literature

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Shan-shan Su ◽  
Guo-qi Zheng ◽  
Ya-gang Liu ◽  
Yue-feng Chen ◽  
Zhao-wei Song ◽  
...  
Keyword(s):  
Malignant Mesothelioma ◽  
Asbestos Exposure ◽  
Peritoneal Mesothelioma ◽  
Liver Involvement ◽  
Review Of Literature ◽  
Malignant Peritoneal Mesothelioma ◽  
Single Institution ◽  
Hepatic Involvement ◽  
Computed Tomography Images ◽  
History Of

Malignant peritoneal mesothelioma with invasion of the liver is an invariably fatal disease. We aimed to clarify the characteristics of malignant peritoneal mesothelioma cases with liver involvement. The clinical presentation, computed tomography images, and immunohistochemical and histopathological features of 5 patients with malignant peritoneal mesothelioma and liver involvement were evaluated. The diagnosis was established by imaging and immune profiles of the tumours. A review of 8 cases with primary or invading malignant mesothelioma in liver is presented. All 5 mesothelioma cases were asbestos-related. CT images of malignant peritoneal mesothelioma with the liver involvement typically showed that the lesion grew inside the liver along the capsule and was possibly accompanied by capsule breakthrough and extrahepatic infiltration. The tumours exhibited a common epithelioid appearance in all 5 patients and most cases revealed positive Cal, CK, and MC with negative CEA and HeP. Different from our findings, the review of literature revealed that most malignant mesothelioma of liver was due to primary intrahepatic malignant mesothelioma. Finally, we concluded that the diagnosis of malignant peritoneal mesothelioma cases with liver invasion is reliably achieved by the history of asbestos exposure, the characteristic CT imaging, and immune profiles of the tumours.

Malignant Peritoneal Mesothelioma in a Hemodialysis Patient with Familial Mediterranean Fever: A Case Report and Literature Review

2008 ◽  
Vol 53 (4) ◽  
pp. 1-3
Author(s):  
E Sengul ◽  
K Yildiz ◽  
Y Topcu ◽  
A Yilmaz
Keyword(s):  
Case Report ◽  
Familial Mediterranean Fever ◽  
Literature Review ◽  
Medical Literature ◽  
Hemodialysis Patient ◽  
Peritoneal Mesothelioma ◽  
Rare Tumor ◽  
Malignant Peritoneal Mesothelioma ◽  
History Of ◽  
Mediterranean Fever

Malignant mesothelioma is a rare tumor. The most common localization of mesothelioma is pleura. It rarely arises from the peritoneum. It has been suggested that familial Mediterranean fever (FMF) may cause the development of peritoneal mesothelioma. We describe a case of malignant peritoneal mesothelioma in a hemodialysis patient with FMF. The patient was a 56 year old female. A history of FMF was present since her childhood. She did not use colchicine and suffered from recurrent ascites. To the best of our knowledge, this is the seventh case of FMF diagnosed as having malignant peritoneal mesothelioma in the medical literature.

scholarly journals Malignant Peritoneal Mesothelioma: Clinicopathological Characteristics of Two Cases

2014 ◽  
Vol 2014 ◽  
pp. 1-3 ◽  
Author(s):  
Mustafa Cem Algın ◽  
Faik Yaylak ◽  
Zülfü Bayhan ◽  
Figen Aslan ◽  
Nilüfer Araz Bayhan
Keyword(s):  
Abdominal Pain ◽  
Asbestos Exposure ◽  
Final Diagnosis ◽  
Clinicopathological Characteristics ◽  
Clinical Findings ◽  
Peritoneal Mesothelioma ◽  
Abdominal Masses ◽  
History Of ◽  
The Right ◽  
Specific Symptoms

Introduction. Peritoneal mesothelioma is a rare tumor, presenting difficulties in diagnosis and treatment. Peritoneum is the second most common area of the mesothelioma after pleura, and even synchronous pleural and peritoneal mesotheliomas are observed in 30–45% of all cases. The diagnosis may be difficult due to lack of specific symptoms and clinical findings. In addition, a delay in the diagnosis is not rare especially in the absence of previous asbestos exposure. Here we report two cases of malignant peritoneal mesotheliomas. The diagnostic and therapeutic approaches for these rare neoplasms are discussed.Case Presentation. The cases were two men (one aged 54 years old and the other 40 years old). Prolonged abdominal pain and swelling were the primary presentation symptoms and findings. The mesotheliomas were developed in the right upper quadrant of abdomen in both of the cases. Both cases were treated with surgical resection. Final diagnosis were possible with histological and immunohistochemical documentation of tumor characteristics, which were consistent with dictating a mesothelial origin. No history of asbestos exposure was reported.Conclusion. Peritoneal mesotheliomas are rare clinical entities. However, patients with prolonged abdominal pain and abdominal masses should be considered to have atypical pathologies such as peritoneal mesotheliomas.

scholarly journals Synchronous multiple primary malignant neoplasms: a case report of malignant peritoneal mesothelioma and neuroendocrine rectal tumor

2021 ◽  
pp. 81-86
Author(s):  
Oleksandr Bondar ◽  
Sergiі Chetverikov ◽  
Viacheslav Maksymovskyi ◽  
Dmytro Atanasov ◽  
Mykhailo Chetverikov ◽  
...  
Keyword(s):  
Minimally Invasive ◽  
Argon Plasma Coagulation ◽  
Asbestos Exposure ◽  
Rectal Tumor ◽  
Peritoneal Mesothelioma ◽  
Special Treatment ◽  
Malignant Neoplasms ◽  
Malignant Peritoneal Mesothelioma ◽  
Invasive Treatment ◽  
Abdominal Tumor

We report a rare case of synchronous malignant peritoneal mesothelioma of the biphasic histological type and neuroendocrine tumor (NET) of the rectum without history of asbestos exposure. During 2 years since manifestation of the disease the patient underwent 3 cytoreductive surgeries (CRS): removal of the tumor of the sigmoid mesentery, resection of the rectosigmoid junction completeness of cytoreduction (CC) 0 (2017), omentectomy and partial parietal peritonectomy CC-0 (2017), atypical resection of S2, S4, S5 liver, the removal of the abdominal tumor with left-sided en-block hemicolectomy, partial parietal peritonectomy, argon-plasma coagulation of tumor foci on the mesentery of the small intestine CC-2 (2018) and Transanal Minimally Invasive Surgery-removal of neuroendocrine rectal tumor (2017). The patient underwent hyperthermic intraperitoneal chemotherapy (HIPEC) twice (during 2nd and 3rd CRS). Different regimens of HIPEC were performed: cisplatin + doxorubicin (2017) and metamycin C (2018). The patient received 4 courses of adjuvant chemotherapy with cisplatin plus pemetrexed in 2017 and 3 courses of the chemotherapy with gemcitabine and carboplatin plus bevacizumab in 2018. The patient survived 21 months after the detection of malignant peritoneal mesothelioma in 2017 and died 4 months after the last cytoreductive surgery from the progression of the disease. Histological subtype of MPMP remains important factor in the prognosis of the disease even on the early stages though patient had received the most aggressive variant of special treatment. Minimally invasive treatment tactics of NET demonstrated clinical effectiveness.  

Malignant peritoneal mesothelioma in a 76-year-old woman with a history of asbestos fiber ingestion

2004 ◽  
Vol 14 (1) ◽  
pp. 162-165
Author(s):  
P. Van Kesteren ◽  
J. Bulten ◽  
C. Schijf ◽  
H. Boonstra ◽  
L. Massuger
Keyword(s):  
Electron Microscopy ◽  
Weight Loss ◽  
Malignant Mesothelioma ◽  
Asbestos Exposure ◽  
Asbestos Fiber ◽  
Malignant Peritoneal Mesothelioma ◽  
Small Tumor ◽  
Contaminated Food ◽  
History Of ◽  
Omental Cake

We report on a woman with malignant mesothelioma of the peritoneum. This is the first report of a subject with this disease who revealed a history of asbestos ingestion by asbestos-contaminated food. She presented with episodes of sweating and fever, ascites, and weight loss. At laparotomy, small tumor deposits were noted on the peritoneum. The omental cake was removed, together with the uterus, ovaries, and tubes which were all macroscopically normal. The diagnosis was established by immunohistochemistry and electron microscopy. Postoperatively, her complaints of fever and sweating disappeared. She refused further chemotherapy. After questioning her for asbestos exposure, she told us that, years ago, she used to prepare vegetables for cooking in rain water collected from a roof made of asbestos.

Differentiation of malignant mesothelioma from adenocarcinoma

1993 ◽  
Vol 51 ◽  
pp. 312-313
Author(s):  
John Garancis ◽  
John Cafaro ◽  
Anthony Cafaro ◽  
Raymond Venezia
Keyword(s):  
Malignant Mesothelioma ◽  
Clinical Course ◽  
Wide Spectrum ◽  
Asbestos Exposure ◽  
Distant Metastases ◽  
Etiologic Agent ◽  
Parietal Pleura ◽  
Metastatic Adenocarcinoma ◽  
Microscopic Appearance ◽  
History Of

Malignant mesothelioma (MM) is a rare tumor arising predominantly from either the visceral or parietal pleura or peritoneal surfaces. It primarily effects individuals between 45 and 75 years. of age and asbestos is felt to be the single most important etiologic agent. Studies suggest that the incidence of MM is increasing perhaps at a rate of as high as 13% per year. The diagnosis of MM can be difficult and is often complicated by the tumors similarity to metastatic adenocarcinoma, both in it's microscopic appearance and to some extent clinical course.In this particular study the immunohistochemical properties of 22 malignant mesotheliomas (20 pleural and two peritoneal) are compared with 20 pulmonary adenocarcinomas. Each tissue was examined using monoclonal antibodies to wide-spectrum cytokeratin, CEA, Leu-M1 and B72.3. Extensive asbestos exposure was identified in all but 1 of the mesothelioma cases. The cases of peritoneal MM were found to have a history of chrysctile exposure only (Fig.1). Distant metastases were present in four cases of MM.

A single-center retrospective cohort study evaluating the role of neoadjuvant chemotherapy in malignant peritoneal mesothelioma.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e21093-e21093
Author(s):  
Xiao Wang ◽  
Sharyn I. Katz ◽  
Leonid Roshkovan ◽  
Suzanne Walker ◽  
Sally McNulty ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cohort Study ◽  
Systemic Therapy ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Asbestos Exposure ◽  
Symptom Relief ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma ◽  
Single Center

e21093 Background: Malignant peritoneal mesothelioma (MPM) is a rare variant of malignant mesothelioma, representing < 30% of cases. Standard of care is cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) when feasible. The benefit of systemic chemotherapy (chemo) (Neoadjuvant- N, Adjuvant- A, or 1st-line metastatic –M) is not well established and some retrospective studies report worse outcomes with N chemo. However, our institution has favored use of N chemo prior to surgery for symptom relief and surgical optimization. We conducted a single-center retrospective cohort study of MPM patients treated at our institution to evaluate the effect of N vs. A chemo on outcomes. Methods: We identified non-papillary MPM patients via ICD9/10 codes seen at our institution between 1/1/2009 and 9/1/2019. Pts were followed until 1/1/2020. Patients without pathologic diagnosis were excluded. We explored the effect of receipt of CRS, type of systemic therapy, and histology on overall survival. Median overall survival (mOS) from diagnosis was estimated from Kaplan-Meier curves. A Cox proportional hazard model computed hazard ratios (HR) to assess the effect of the exposure on OS. Results: We identified 47 patients with non-papillary MPM: median age 62 years, 77% epithelioid histology, 74.5% white, 55.3% known asbestos exposure. CRS was performed in 24 (51%) and 18/24 (75%) received HIPEC. The majority received systemic therapy (34/47 (72%)). Among those that received chemo and surgery, N chemo was more common than A chemo (N:12 (all platinum/pemetrexed), A:7). Median OS was 52.7 months (mo) overall and 77.2 mo with surgery vs 20.2 mo without (log rank p = 0.006). Toxicity from N chemo did not prevent surgery with 8/12 successfully receiving surgery (1 surgery scheduled, 2 lost to follow up). Of the 10 pts with evaluable scans: 5 had radiographic reduction of disease (2 complete responses by RECIST 1.1), 4 stable disease and 1 with disease growth. N chemo reduced ascites in 3 out of 4 pts with baseline ascites. N chemo was not associated with worse mOS compared to A chemo (HR 0.64, 95% CI 0.1-3.0, p = 0.62). Non-epithelioid histology was not associated with a worse OS compared to epithelioid (HR 1.5, 95% CI 0.6-4.1, p = 0.4). Conclusions: N chemo was not associated with worse outcomes compared to A chemo and toxicity from N chemo did not preclude surgery. In addition, N chemo resulted in reduction of disease burden and ascites in pts with MPM.

Sign in / Sign up

Export Citation Format

Share Document